-
公开(公告)号：KR101699567B1
公开(公告)日：2017-01-24
申请号：KR1020120012268
申请日：2012-02-07
Applicant: 가톨릭대학교 산학협력단
IPC: A61K48/00 , A61K39/395
Abstract: 본발명은 JunB의발현또는활성억제제를유효성분으로포함하는면역질환의예방또는치료용조성물에관한것으로서보다구체적으로본 발명은 JunB 유전자의 mRNA에상보적으로결합하는안티센스뉴클레오티드, 작은간섭 RNA(short interfering RNA), 짧은헤어핀 RNA(short hairpin RNA) 및 JunB 단백질에대한항체로이루어진군 중에서선택되는어느하나를포함하는면역질환의예방또는치료용약학적조성물및 이를이용한면역질환의예방또는치료방법에관한것이다. 본발명에따르면, JunB의발현또는활성을억제하는경우면역질환을유발하는 Th17 세포의분화를억제하고, 염증성사이토카인인 IL-17의생성을억제하며, 염증성자가항체를억제하고, 항원에의한면역세포의증식을억제하는활성이우수하여, 면역조절이상으로유발되는각종면역질환을치료하기위한치료제의제조에널리활용할수 있다.
Abstract translation: 目的：提供一种用于预防和治疗JunB的表达或活性抑制剂的免疫疾病的组合物，用于制备用于治疗JunB的表达或活性时异常免疫控制引起的各种免疫疾病的药物 抑制。 构成：用于预防和治疗免疫疾病的组合物包含选自下组中的至少一种：与JunB基因互补结合的基因JunB的mRNA，短干扰RNA，短发夹RNA和针对JunB的抗体 蛋白。 基因JunB由SEQ ID NO：1的多核苷酸形成。 SEQ ID NO：1的多核苷酸编码SEQ ID NO：2的多肽。
-
公开(公告)号：KR1020130129496A
公开(公告)日：2013-11-29
申请号：KR1020120053393
申请日：2012-05-21
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/155 , A61K31/09 , A23L1/30
CPC classification number: A61K31/155 , A23L33/10 , A23V2002/00 , A23V2200/324 , A61K31/09 , A61K2121/00 , A61K2300/00
Abstract: The present invention relates to a pharmaceutical use of a metformin compound used to prevent or treat immune diseases caused by abnormal immune responses, and more particularly, to a composition for preventing or treating immune diseases comprising a metformin compound as an active gradient. The metformin compound has excellent effects of inhibiting the differentiation into cytotoxic Th17 cells that generate and secrete inflammatory cytokine; enhancing activity of immunoregulatory T cells (Treg) that inhibit functions of abnormally activated immune cells and regulate inflammatory responses; and effectively maintaining and enhancing functions of the immunoregulatory T cells (Treg) through inhibition of plasticity of differentiation of the immunoregulatory T cells (Treg) into Th17 cells. Therefore, the metformin compound is useful as a pharmaceutical composition or an immune inhibitor capable of preventing or treating immune diseases caused by abnormal regulations of various immune responses, such as autoimmune diseases, inflammatory diseases, and transplant rejection disorders.
Abstract translation: 本发明涉及用于预防或治疗由免疫反应异常引起的免疫疾病的二甲双胍化合物的药物用途，更具体地涉及包含二甲双胍化合物作为活性梯度的预防或治疗免疫疾病的组合物。 二甲双胍化合物具有抑制分化为产生和分泌炎性细胞因子的细胞毒性Th17细胞的优异效果; 增强抑制异常活化免疫细胞功能和调节炎症反应的免疫调节性T细胞（Treg）的活性; 通过抑制免疫调节性T细胞（Treg）分化为Th17细胞的可塑性，有效维持和增强免疫调节性T细胞（Treg）的功能。 因此，二甲双胍化合物可用作能够预防或治疗由诸如自身免疫性疾病，炎性疾病和移植排斥障碍等各种免疫应答的异常调节引起的免疫疾病的药物组合物或免疫抑制剂。
-
公开(公告)号：KR1020130122555A
公开(公告)日：2013-11-07
申请号：KR1020130045995
申请日：2013-04-25
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/12 , C12N5/0783 , A61P37/00
Abstract: The present invention relates to novel uses of curcumin which inhibits differentiation plasticity of regulatory T cells (Treg) and, specifically, to a composition for suppressing differentiation of regulatory T cells (Treg) including curcumin as an active ingredient into etiology cells; a composition for preventing or treating autoimmune diseases including curcumin and regulatory T cells (Treg) as active ingredients; a method of manufacturing regulatory T cells (Treg) which maintains immune suppressing function using curcumin; and a method for suppressing conversion of regulatory T cells (Treg) into etiology cells by using curcumin. The curcumin according to the present invention has a novel use which effectively maintains and reinforces the functions of regulatory T cells (Treg) by suppressing differentiation plasticity of the regulatory T cells into etiology cells so that the curcumin can block differentiation of regulatory T cells (Treg) into etiology cells and maximize effects of preventing or treating autoimmune diseases when the curcumin is used in parallel with the regulatory T cells (Treg) which are cell therapy products. In addition, the curcumin is a natural substance so that the curcumin can be used for long time without toxicity and side effects and have stable effects on body.
Abstract translation: 本发明涉及抑制调节性T细胞（Treg）的分化可塑性的姜黄素的新用途，具体地，涉及抑制作为活性成分的姜黄素调节性T细胞（Treg）分化为病因细胞的组合物; 用于预防或治疗包括姜黄素和调节性T细胞（Treg）作为活性成分的自身免疫性疾病的组合物; 使用姜黄素维持免疫抑制功能的调节性T细胞（Treg）的制备方法; 以及通过使用姜黄素抑制调节性T细胞（Treg）转化为病因细胞的方法。 根据本发明的姜黄素具有通过抑制调节性T细胞向病因细胞的分化可塑性而有效维持并增强调节性T细胞（Treg）的功能的新用途，使得姜黄素可以阻断调节性T细胞（Treg）的分化 ）进入病因细胞，并且当姜黄素与作为细胞治疗产品的调节性T细胞（Treg）并行使用时，预防或治疗自身免疫性疾病的效果最大化。 此外，姜黄素是天然物质，因此姜黄素可长时间使用，无毒副作用，对身体有较好的疗效。
-
公开(公告)号：KR1020130122446A
公开(公告)日：2013-11-07
申请号：KR1020120045791
申请日：2012-04-30
Applicant: 가톨릭대학교 산학협력단
IPC: C12N5/0783 , C07D307/79 , A61K35/12
CPC classification number: C12N5/0646 , A61K35/12 , C07D307/79 , C12N2502/1114
Abstract: The present invention relates to a novel use of tanshinone IIA which suppresses differentiation plasticity of regulatory T cells (Treg) and, specifically, to a composition containing tanshinone IIA as an active ingredient for suppressing differentiation of Treg cell into Th17 cells; a composition containing tanshinone IIA and Treg cells as active ingredients for preventing or treating immune diseases; and a method for producing Treg cells using tanshinone IIA, in which immunosuppressive function is maintained. According to the present invention, tanshinone IIA effectively maintains and enhances the function of Treg cells by suppressing differentiation plasticity of Treg cells into Th17 cells, thereby blocking differentiation of Treg cells into Th17 cells under a pathological condition when being alternately used with Treg cells and providing a therapeutic agent for effectively treating immune diseases.
Abstract translation: 本发明涉及抑制调节性T细胞（Treg）的分化可塑性的新丹西酮IIA的新用途，具体地，涉及含有丹参酮IIA作为抑制Treg细胞分化为Th17细胞的活性成分的组合物的新用途。 含有丹参酮IIA和Treg细胞作为预防或治疗免疫疾病的有效成分的组合物; 以及维持免疫抑制功能的使用丹参酮IIA的Treg细胞的制造方法。 根据本发明，丹参酮IIA通过抑制Treg细胞分化为Th17细胞的可塑性，有效维持和增强Treg细胞的功能，从而在与Treg细胞交替使用时在病理条件下阻断Treg细胞分化为Th17细胞，并提供 用于有效治疗免疫疾病的治疗剂。
-
公开(公告)号：KR101463325B1
公开(公告)日：2014-11-20
申请号：KR1020130003938
申请日：2013-01-14
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K38/482 , C12N9/6424 , C12Y304/21108
Abstract: 본 발명은 HtrA2 단백질을 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 조성물에 관한 것이다. 본 발명에 따른 HtrA2(High temperature requirement protein A2) 단백질은 HtrA2 단백질이 Th17 세포의 전사인자인 STAT3의 발현을 감소시키고 염증성 사이토카인의 발현을 억제시키며, 조절 T 세포(Regulatory T cell: Treg)의 활성을 촉진시켜 과도한 면역반응을 조절하는 기작을 통해 이루어지므로, 염증반응 및 각종 면역반응의 조절 이상으로 유발되는 자가면역질환을 효과적으로 치료할 수 있는 효과가 있다.
-
Patent Agency Ranking
公开(公告)号：KR101432892B1
公开(公告)日：2014-08-21
申请号：KR1020120102887
申请日：2012-09-17
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/155 , A61P37/00
CPC classification number: A61K31/155
Abstract: 본 발명은 메트포민(metformin)에 의해 유도되는 B 세포 활성 억제를 통한 면역질환의 예방 또는 치료용 조성물에 관한 것으로, 좀 더 상세하게는 메트포민(metformin) 화합물 또는 그의 약학적으로 허용 가능한 염을 유효성분으로 포함하되, 상기 조성물은 병인 B 세포의 활성을 억제 또는 감소시키는 것을 특징으로 하는 면역질환의 예방 또는 치료용 조성물에 관한 것이다.
본 발명에 의하면 다양한 자가면역질환에서 병인 B 세포의 활성을 억제 또는 감소시키고, 병인 Th17 세포의 활성을 억제 또는 감소시키거나, 조절 T 세포(Regulatory T cell:Treg)의 활성을 촉진 또는 증가시킴으로써 면역질환을 예방 또는 치료할 수 있는 면역 억제제로 유용하게 사용될 수 있을 것이다.-
公开(公告)号：KR101317492B1
公开(公告)日：2013-10-15
申请号：KR1020110049894
申请日：2011-05-26
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/166 , A61K31/16 , A61K31/06 , A61P21/00
Abstract: 본 발명은 AG490 화합물을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물에 관한 것으로서, 보다 구체적으로 본 발명은 AG490 화합물을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물에 관한 것이다. 본 발명에 따른 AG490 화합물은 염증성 사이토카인을 생성 및 분비하는 병인성 Th17 세포의 분화를 억제하는 효과가 우수하고, 비정상적으로 활성화된 면역세포의 기능을 억제하고 염증 반응을 제어하는 특성을 갖는 면역조절 T 세포(Treg)의 활성을 증진시키는 효과가 우수하면서도 p53 유전자의 발현을 촉진시키므로 각종 면역반응의 조절 이상으로 유발되는 자가면역질환, 염증성질환 및 이식거부질환과 같은 면역질환을 예방 또는 치료할 수 있는 약학적 조성물 또는 면역 억제제로 유용하게 사용할 수 있다.
-
公开(公告)号：KR1020130091044A
公开(公告)日：2013-08-16
申请号：KR1020120012268
申请日：2012-02-07
Applicant: 가톨릭대학교 산학협력단
IPC: A61K48/00 , A61K39/395
CPC classification number: A61K48/005 , A61K39/3955 , A61K2121/00
Abstract: PURPOSE: A composition for prevention and treatment of an immune disease including an expression or activity inhibitor of JunB is provided to be used in manufacture of a medicine for treating various immune diseases that are caused by an abnormal immune control when expression or activity of JunB is inhibited. CONSTITUTION: A composition for prevention and treatment of an immune disease comprises at least one selected from the group consisting of an antisense nucleotide complementarily binding to mRNA of gene JunB, a short interfering RNA, a short hairpin RNA, and an antibody with respect to JunB protein. The gene JunB is formed of polynucleotides of SEQ ID NO:1. The polynucleotides of the SEQ ID NO: 1 code a polypeptide of SEQ ID NO:2.
Abstract translation: 目的：提供一种用于预防和治疗JunB的表达或活性抑制剂的免疫疾病的组合物，用于制备用于治疗JunB的表达或活性时异常免疫控制引起的各种免疫疾病的药物 抑制。 构成：用于预防和治疗免疫疾病的组合物包含选自下组中的至少一种：与JunB基因互补结合的基因JunB的mRNA，短干扰RNA，短发夹RNA和针对JunB的抗体 蛋白。 基因JunB由SEQ ID NO：1的多核苷酸形成。 SEQ ID NO：1的多核苷酸编码SEQ ID NO：2的多肽。
-
公开(公告)号：KR1020120026208A
公开(公告)日：2012-03-19
申请号：KR1020100088295
申请日：2010-09-09
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/015 , A61P35/00
Abstract: PURPOSE: A composition containing STA-21 for preventing or treating cancer or immune diseases is provided to suppress cytotoxic Th17 cell differentiation and to control inflammation. CONSTITUTION: A composition for preventing and treating cancer or immune diseases contains STA-21 compounds of chemical formula 1 or pharmacetuically acceptable salt thereof as an active ingredient. The STA-21 promotes or increases activation or amplification of regulatory T cells. A method for reducing or suppressing differentiation of undifferentiated T cells into Th17 cells in vitro comprises a step of treating STA-21 compounds or pharmaceutically acceptable salt thereof to the undifferentiated cells. A composition for anticancer or immunodepression contains STA-21 compounds or pharmaceutically acceptable salt thereof as an active ingredient.
Abstract translation: 目的：提供含有用于预防或治疗癌症或免疫疾病的STA-21的组合物，以抑制细胞毒性Th17细胞分化并控制炎症。 构成：用于预防和治疗癌症或免疫疾病的组合物含有化学式1的STA-21化合物或其药学上可接受的盐作为活性成分。 STA-21促进或增加调节性T细胞的活化或扩增。 未分化T细胞在体外分化为Th17细胞的方法包括将STA-21化合物或其药学上可接受的盐处理至未分化细胞的步骤。 用于抗癌或免疫抑制的组合物含有STA-21化合物或其药学上可接受的盐作为活性成分。
-
-
-
-
-
-
-
-
-
Search Results
37
records
(took 0.023 seconds)
